[{"from": "human", "value": "What can you tell me about this molecule? [C][C][C][S][=Branch1][C][=O][=Branch1][C][=O][N][C][=C][Branch2][Ring2][#Branch2][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][C][=Branch1][C][=O][C][=C][N][C][=C][Ring1][Branch1][C][=C][Branch1][Branch1][C][=N][Ring1][=Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][F]"}, {"from": "gpt", "value": "The molecule is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program."}]